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Abstract: The present randomized controlled study aimed to investigate the in vivo distribution of
constituents or metabolites of the standardized maritime pine bark extract Pycnogenol®. Thirty-three
patients with severe osteoarthritis scheduled for a knee arthroplasty were randomized to receive
either 200 mg per day Pycnogenol® (P+) or no treatment (Co) over three weeks before surgery.
Serum, blood cells, and synovial fluid samples were analyzed using liquid chromatography
coupled to tandem mass spectrometry with electrospray ionization (LC-ESI/MS/MS). Considerable
interindividual differences were observed indicating pronounced variability of the polyphenol
pharmacokinetics. Notably, the highest polyphenol concentrations were not detected in serum.
Catechin and taxifolin primarily resided within the blood cells while the microbial catechin metabolite
δ-(3,4-dihydroxy-phenyl)-γ-valerolactone, ferulic, and caffeic acid were mainly present in synovial
fluid samples. Taxifolin was detected in serum and synovial fluid exclusively in the P+ group.
Likewise, no ferulic acid was found in serum samples of the Co group. Calculating ratios of analyte
distribution in individual patients revealed a simultaneous presence of some polyphenols in serum,
blood cells, and/or synovial fluid only in the P+ group. This is the first evidence that polyphenols
distribute into the synovial fluid of patients with osteoarthritis which supports rationalizing the
results of clinical efficacy studies.
Keywords: pine bark extract; LC-ESI/MS/MS; randomized controlled study; osteoarthritis;
human; polyphenols
1. Introduction
Dietary polyphenols have been associated with numerous beneficial effects on human health.
Studies investigating the absorption of polyphenols from the gastrointestinal tract revealed that blood
concentrations of individual polyphenols are often very low [1]. Moreover, polyphenolic compounds
are often subjected to an extensive metabolism [2]. Some metabolites generated by gut microbial
metabolism obviously contribute to health effects [3].
One of those bioactive metabolites is δ-(3,4-dihydroxy-phenyl)-γ-valerolactone (M1) which is formed
by the human intestinal flora from the procyanidins’ catechin units [2]. It has been detected in
urine and plasma samples after intake of Pycnogenol® [4,5]. The dietary supplement Pycnogenol®
is a standardized extract of the French maritime pine, which conforms to the monograph
“Maritime pine extract” in the United States Pharmacopeia (USP). It contains 65%–75% oligomeric
procyanidins and polyphenolic monomers, phenolic, or cinnamic acids and their glycosides [6].
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In numerous clinical studies Pycnogenol® demonstrated effects in different chronic diseases of,
for example, inflammatory or cardiovascular origin [6,7].
Another chronic disease with high pharmacoeconomic burden and significant impact on the
patients’ quality of life is osteoarthritis (OA). OA is a chronic degenerative joint disease which is
characterized by progressive cartilage destruction and it is the leading cause of pain and disability [8].
Treatment of OA includes pharmacological and non-pharmacological interventions and aims at pain
relief and improvement of function. Severe OA might also require surgical interventions such as
knee or hip arthroplasty [9]. Dietary factors or supplements have been discussed as options in the
management or prevention of OA [10].
In clinical studies OA symptoms such as pain and joint stiffness have been shown to improve upon
intake of Pycnogenol® [11,12]. While this clinical observation is consistent with a previously shown
inhibition of nuclear factor κB (NF-κB) activation and inhibition of various matrix metalloproteinases
by constituents or metabolites of this pine bark extract [13,14], it is not clear yet whether bioactive
polyphenols would actually be present at the site of disease (e.g., in the joints affected by OA). After an
oral intake of multiple doses of Pycnogenol® concentrations in the nanomolar range of catechin,
taxifolin, caffeic acid, ferulic acid, and of a bioactive metabolite M1 have been detected in human
plasma [5]. Moreover, an uptake of M1 into erythrocytes, monocytes, and endothelial cells has been
observed in vitro [15,16]. The purpose of the current study was to investigate the in vivo distribution
of constituents or metabolites of Pycnogenol® in serum, blood cells, and synovial fluid of patients with
severe OA scheduled for a knee replacement surgery.
2. Materials and Methods
2.1. Clinical Study Design
The present study was a randomized controlled clinical trial involving patients with severe
osteoarthritis (OA) according to the Western Ontario and McMaster Universities Arthritis Index
(WOMAC) score, who were scheduled for an elective knee replacement surgery (Kellgren-Lawrence
grade III–IV). Patients were not eligible if they regularly took non-steroidal anti-inflammatory drugs
(NSAIDs) or glucocorticoids perorally within the past four weeks, if they currently received a therapy
with anti-coagulants, or if they tested positive for the human immunodeficiency virus (HIV), hepatitis
B or C, or if they had a previous or current infection of the affected knee joint. As rescue medication
acetaminophen (paracetamol), tramadol, or a combination of tilidine and naloxone was allowed.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the local Ethics Committee of the Medical Faculty of the University Würzburg (Project
identification code 248/11).
A total of 33 OA patients were recruited for the study and gave informed written consent before
they participated in the study. The chosen number of patients was based on a previous pharmacokinetic
study with healthy volunteers receiving the pine bark extract [5]. Patients were randomized into two
groups using a computer-generated randomization list which was not accessible to the physicians
and nurses who were involved in the patient care and management. Study participants (n = 16) were
assigned to the treatment group receiving 200 mg of the French maritime pine bark extract Pycnogenol®
(Horphag Research Ltd., Geneva, Switzerland) per day (twice daily two capsules with each 50 mg)
over three weeks prior to the planned surgery. The control group was comprised of 17 patients who
did not receive Pycnogenol®. All patients were asked to comply with a polyphenol-free nutrition,
especially two days before each blood sampling. For this purpose, they were provided with nutritional
check-lists specifying food/beverages they should avoid and for recording what they ingested within
the last two days before blood sampling. Adherence to the study medication was estimated based on
the number of returned Pycnogenol® capsules upon hospitalization for the knee replacement surgery.
Blood samples from each study participant were collected (BD Vacutainer® SST II Advance;
Becton Dickinson GmbH, Heidelberg, Germany) before oral intake of Pycnogenol® (V1, basal value);
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during the intake, approximately 1–2 days before the surgery (V2); and during or shortly before knee
surgery (V3), about 12 h after the last dose of Pycnogenol®. Immediately after blood sampling the
serum and cellular fraction were separated under sterile conditions. On the day of the surgery residual
knee cartilage and synovial fluid were also collected. All samples were shock-frozen immediately and
stored at −80 ◦C. The outcome measure was the concentration of pine bark extract-derived polyphenols
in serum, blood cells, and synovial fluid as determined by liquid chromatography coupled to tandem
mass spectrometry with electrospray ionization (LC-ESI/MS/MS).
All medical procedures including enrollment of participants, surgery, patient care,
and sample collection took place at the orthopedic center (Orthopädie und Orthopädische
Klinik König-Ludwig-Haus, Universität Würzburg) between September 2012 and September 2014.
The generation of the random allocation sequence, assignment of participants to the intervention
or control group, and analysis of all patient samples took place at the Institut für Pharmazie und
Lebensmittelchemie. Since the study primarily focused on pharmacokinetic/bioanalytical aspects,
specifically on the analysis of polyphenols in various human specimen, an early registration was
overlooked and the study was registered retroactively.
2.2. Chemicals, Reagents, and Special Materials
Analytical standards of (+)-catechin, taxifolin, ferulic acid, caffeic acid, and the internal
standard (IS) 3,4-dihydroxyhydrocinnamic acid (hydrocaffeic acid) were all obtained from
Sigma-Aldrich (Taufkirchen, Germany). The metabolite M1 (δ-(3.4-dihydroxy-phenyl)-γ-valerolactone)
was synthesized by M. Rappold as part of his diploma thesis. Methanol (MeOH, LC-MS analyzed)
from J.T.Baker Mallinckrodt and water (HiPerSolv CHROMANORM® for LC-MS) were obtained from
VWR (Darmstadt, Germany). Ammonium formate (AF) and formic acid (FA) were purchased from
Sigma-Aldrich. An enzymatic mixture of β-glucuronidase/sulfatase (β-Gln/Sulfa) from Helix pomatia
(Type HP-2; Sigma-Aldrich) was used for enzymatic hydrolysis. Ethyl acetate, tert-butyl methyl ether
(MTBE), and phosphate buffered saline (PBS, pH 7.4) were obtained from Sigma-Aldrich.
2.3. Standard Solutions
Stock solutions (1 mg/mL) of each standard substance ((+)-catechin, taxifolin, ferulic acid,
caffeic acid, and M1) and of the internal standard (IS; hydrocaffeic acid) were prepared in 100%
methanol and stored at −80 ◦C. They were diluted with methanol to yield working standards which
were aliquoted and stored at −20 ◦C.
2.4. Human Specimen for Calibration Curves
Packed cells and serum were obtained from a blood bank (Bayerisches Rotes Kreuz (BRK),
München, Germany) and handled as previously described [17,18]. Synovial fluid was collected from
patients with intra-articular fluid accumulation who needed punctuation of the effusion for medical
reasons. Synovial fluid samples were pooled to obtain a single batch for preparation of calibration
standards for quantification of the clinical study samples.
2.5. Liquid Chromatography (LC)
Details of the LC method have been reported before [18,19]. Briefly, for the LC analysis an Agilent
1260 system was used. The chromatographic separation was carried out using a Pursuit PFP-C18
column (4.6 × 150 mm, particle size 3 µm) at 20 ◦C (all from Agilent Technologies, Santa Clara,
CA, USA). The mobile phase consisted of 5 mM ammonium formate with 0.065% (v/v) formic acid
(pH = 3.2; A) and methanol with 0.1% formic acid (B). The flow rate was set to 0.6 mL/min and the
sample injection volume was 5 µL. The gradient elution was conducted starting at 60% B (0 min) to
95% B (2.50 min) and maintained to 95% B to 5.50 min followed by re-equilibration at 60% B. The total
run time was 10.00 min with a post time of 3 min.
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2.6. Mass Spectrometry (MS/MS)
Details of the MS/MS method using a G 6460 TripleQuad LC/MS with turbo electrospray
ionization (ESI; Agilent Technologies, Santa Clara, CA, USA) have been previously reported [17,18].
The optimized MS/MS transitions and mass spectrometric parameters of the compounds to be
quantified in human blood cell and serum samples were recently reported [18,19]; optimized
parameters of additionally determined M1 metabolites in blood cells are listed in Table S1 in the
electronic supplementary material. Optimized MS/MS transitions and mass spectrometric parameters
of the compounds to be quantified in human synovial fluid samples are listed in Table S2.
2.7. Preparation of Human Serum Samples
Serum samples (1.5 mL) were prepared by liquid-liquid extraction with prior enzymatic incubation
containing β-Gln/Sulfa to hydrolyze conjugated analytes [5], as previously described [18,19].
Additionally, 1.5 mL of serum was analyzed without prior enzymatic hydrolysis to calculate the
degree of conjugation with sulfate and glucuronic acid.
2.8. Preparation of Human Blood Cell Samples
Human blood cell samples were prepared as previously detailed [18]. Therefore, 2.0 mL blood
cells of each study volunteer were processed with prior enzymatic hydrolysis to determine the total
concentration of the analytes.
2.9. Preparation of Human Synovial Fluid Samples
Synovial fluid samples were prepared with a newly developed and optimized liquid-liquid
extraction method. Therefore, 40 µL 4% o-phosphoric acid was added to 1.0 mL human synovial fluid
(pH 5.0). Afterwards, the samples were incubated with an enzyme mixture containing β-Gln/Sulfa
(1500 U β-Gln and 2 U Sulfatase per mL synovial fluid) for 45 min at 37 ◦C on a horizontal shaker
(100 rpm) to hydrolyze conjugated analytes [5]. Then, 60 µL 4% o-phosphoric acid (pH 3.2), 25 µL
IS (24.85 ng/mL), and 3.0 mL extraction solvent containing ethyl acetate and tert-butyl methyl ether
(1:1; v/v) were added, vortexed for 1 min (Multi-Vortex, VWR, Darmstadt, Germany), and centrifuged
for 5 min at 3300× g (4 ◦C). Thereafter, 2.0 mL of the upper organic layer was evaporated to dryness
under nitrogen. The residue was reconstituted in 75 µL of 100% MeOH and centrifuged at 18,000× g
for 15 min at 4 ◦C before LC-MS/MS analysis.
A full validation was performed for the quantification of the analytes in human synovial fluid
with the optimized liquid-liquid extraction method and prior enzymatic hydrolysis. The validation
included the selectivity, linearity, lower limit of quantification (LLOQ), accuracy and precision
(intra- and interday), recovery, process efficiency, matrix effects (quantitative), carry over, cross talk,
and post-preparative stability. Also, the freeze- and thaw-, short-term-, and long-term stability of the
analytes in human serum were investigated.
2.10. Quantification of the Samples of the Study Participants
For each patient, specimen human pooled matrix-matched calibration standards with an internal
standard (structural) were used for quantification of the study samples. In case of a basal presence of
an analyte in the blank matrix, the calibration curve was shifted along the y axis by the response of the
zero-sample (containing the IS) [20].
2.11. Statistical Analysis
Data were analyzed using descriptive statistics. Typically, mean and standard deviation (SD) were
calculated. For comparison of the study participants’ basic demographic characteristics a Student’s
t-test was used to compare the patients of the treatment and control group.
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3. Results
3.1. Patients and Protocol Adherence
A total of 33 patients were enrolled into the study and randomized to receive either Pycnogenol®
(n = 16) or no treatment (n = 17). One patient of the control group decided against the scheduled
knee replacement surgery and was excluded. During the surgical procedure, there was a failure to
collect blood, synovial fluid, and cartilage samples for one patient in both the control group and the
Pycnogenol® group. These patients were excluded from the analysis (Figure 1). Thus, 30 patients
(66.7% female) underwent analysis after receiving Pycnogenol® (“P+”; 9 females, 6 males) or no
treatment as the control group (“Co”; 11 females, 4 males). There was no statistically significant
difference between the groups in any of the basic demographic characteristics (Student’s t-test, p > 0.05),
the mean age (± standard deviation SD) was 64.3 ± 8.2 years, height 1.69 ± 0.10 m, body weight
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Figure 1. CONSORT (Consolidated Standards of Reporting Trials; www.consort-statement.org)
2010 Flow diagram of the study.
All study participants were requ sted to avoid poly henol-rich food/beverages (e.g., coffee, green
tea, wine, chocolate, s me fruits and vegetables) within the last two days before the blood samplings.
Analysis of the utriti n protocols revealed that the nutri ional advice was not followed well and
dietary violations were admitted before collecting 42% of the blood samples. Thus, concentrations of
common polyphenols such as catechin or caffeic acid from other sources than Pycnogenol® were to be
expected in the blood samples.
In contrast, the adherence to the study medication was excellent based on the pill count-back
on returned medication containers. In the Pycnogenol® group the average adherence was 99.4%
(range 96%–100%) for all but one study participant who apparently took only 76% of the capsules.
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No treatment-associated adverse effects were reported except for one patient of the Pycnogenol® group
who experienced flatulence.
3.2. Method for Analysis of Polyphenols in Human Synovial Fluid Samples
To the best of our knowledge, this is the first study describing the detection and quantification of
polyphenols in human synovial fluid. Since concentrations in synovial fluid samples were possibly
lower than in blood and based on the fact that a previous pharmacokinetic study revealed plasma
concentrations of polyphenolic compounds in the nanomolar range after intake of Pycnogenol® [5],
a highly sensitive method was required. In the course of method development, the main focus was the
optimal detection and quantification of the metabolite M1.
Analogous to previously developed methods for analysis of Pycnogenol® polyphenols in
serum and blood cells [18,19], various sample preparation techniques were compared and a
liquid-liquid extraction method was chosen. For the analytes of highest interests, the lower limits
of quantification (LLOQs) in synovial fluid were 0.080 ng/mL for taxifolin and 0.117 ng/mL for M1
(Table 1 and Table S9). The method was slightly less sensitive for ferulic acid (LLOQ of 1.53 ng/mL),
catechin (2.14 ng/mL), and caffeic acid (3.07 ng/mL).
Table 1. Lower limits of quantification (LLOQs) of polyphenolic analytes of highest interest. Data for
serum and blood cells was derived from previous work [18,19].
Analyte LLOQ Synovial Fluid (ng/mL) LLOQ Serum (ng/mL) LLOQ Blood Cells (ng/mL)
Catechin 2.14 5.86 28.90
M1 0.12 0.16 0.12
Taxifolin 0.08 0.06 0.12
Caffeic Acid 3.07 8.22 48.40
Ferulic Acid 1.53 2.74 0.97
In the supplementary materials, details about the recovery, matrix effects, and process efficiency
(Tables S10 and S11), as well as the internal standard normalized matrix factor (Table S12) in pooled and
individual lots of synovial fluid are documented. The method was validated based on current EMA
(European Medicines Agency) and FDA (US Food and Drug Administration) guidelines and complied
with the requirements for selectivity, linearity (Table S3), precision and accuracy (Tables S6 and S7),
robustness (Table S6), carry-over, cross-talk, and post-preparative stability (Tables S9 and S10).
Representative chromatograms of all three specimens of an individual study participant after
multiple dosing of 200 mg/day Pycnogenol® over the course of three weeks (P+, V3) revealed total
concentrations of 23.17 ng/mL catechin, 3.70 ng/mL ferulic acid, 0.19 ng/mL taxifolin, 0.16 ng/mL
M1 in serum, 74.31 ng/mL catechin, 1.93 ng/mL ferulic acid, and 0.57 ng/mL taxifolin in blood cells,
and 3.19 ng/mL ferulic acid, 0.18 ng/mL taxifolin, and 0.17 ng/mL M1 in synovial fluid (Figure 2).
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Figure 2. Example chromatograms for qua tifi ti i t e thr e different sample matrices f one
individual study participant after multiple dosing of 200 mg/day Pycnogenol® over the course of three
weeks (P+, V3). (A) Serum; (B) Blood cells; (C) Synovial fluid.
3.3. Pycnogenol® Constituents and Metabolites in Serum Samples
In the basal serum samples (V1) the mean total concentrations (free and conjugated) of all study
participants were 27.07 ± 16.39 ng/mL catechin (mean and standard deviation), 1.80 ± 2.63 ng/mL for
M1, 0.07 ng/mL (n = 1) for taxifolin, 6.40 ± 2.58 ng/mL for ferulic acid, and 18.58 ± 6.32 ng/mL
for caffeic acid. For example, catechin was detectable in 29 out of 30 V1 samples, and in
24 samples the concentrations were above 10 ng/mL. Thereby, catechin was primarily present as
glucuronide-/sulfate-conjugate. When only the free concentratio s were regarded, catechin was
detectable in 20 out of 30 V1 samples, and in 11 samples he concentra ions were above 10 ng/mL.
There were no apparent differences in the basal concentra ions between the participants ass gned to
the P+ or Co group. Ev n whe disregarding those patients who admitted a violation of the dietary
restrictions there were still considerable basal concentrations present in serum.
The analysis of serum samples obtained after three weeks (V3) of Pycnogenol® intake revealed
the highest concentrations for catechin, followed by caffeic acid, ferulic acid, M1, and taxifolin (Table 2,
panel A). Although there was a tendency of higher concentrations of catechin in the P+ compared
to the control group, the serum concentrations of M1 and caffeic acid in the control group exceeded
those in the P+ group (Table 2, panel A). When patients who admitted intake of, for example, coffee,
green tea, or chocolate were excluded from the analysis the trend of higher catechin levels as well as
clearly higher concentrations of M1 in the P+ group became obvious and caffeic acid was not even
detectable in the control group (Table 2, panel B).
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Table 2. Results of the sample analysis in serum, blood cells, and synovial fluid of patients taking Pycnogenol® 200 mg/day (P+) and control patients (Co) receiving
no supplement. The population numbers (n) indicate the number of patients with detectable concentrations of the respective polyphenol. A: Total mean concentrations
and standard deviations (SD) determined after three weeks (V3) without exclusion of patients who admitted violations of the dietary restrictions; B: Total mean
concentrations and SD determined after three weeks (V3). Patients who admitted violations of the dietary restrictions in their nutritional protocols were excluded.
n.d.: not detected; Conc.: concentration.
A Catechin M1 Taxifolin Ferulic Acid Caffeic Acid
Conc. (ng/mL) ± SD Conc. (ng/mL) ± SD Conc. (ng/mL) ± SD Conc. (ng/mL) ± SD Conc. (ng/mL) ± SD
Serum
P+ 52.53 ± 18.40 n = 15 0.54 ± 0.84 n = 9 0.20 ± 0.12 n = 5 3.02 ± 0.39 n = 7 9.28 ± 0.51 n = 3
Co 45.85 ± 39.59 n = 15 1.07 ± 1.09 n = 5 n.d. - n.d. - 14.84 ± 1.92 n = 3
Blood Cells
P+ 71.18 ± 27.34 n = 14 0.19 ± 0.07 n = 12 0.52 ± 0.23 n = 15 1.86 ± 0.36 n = 10 n.d. -
Co 70.48 ± 36.22 n = 13 0.21 ± 0.05 n = 5 0.48 ± 0.32 n = 15 1.80 ± 0.85 n = 7 n.d. -
Synovial Fluid P+ 2.99 ± 0.43 n = 4 0.62 ± 0.77 n = 5 0.21 ± 0.03 n = 2 4.29 ± 1.83 n = 8 10.32 ± 3.96 n = 7
Co 3.94 ± 1.83 n = 2 0.78 ± 0.74 n = 4 n.d. - 3.04 ± 0.79 n = 6 12.83 ± 8.95 n = 10
B Catechin M1 Taxifolin Ferulic Acid Caffeic Acid
Conc. (ng/mL) ± SD Conc. (ng/mL) ± SD Conc. (ng/mL) ± SD Conc. (ng/mL) ± SD Conc. (ng/mL) ± SD
Serum
P+ 48.41 ± 18.61 n = 11 0.70 ± 1.02 n = 6 0.20 ± 0.12 n = 5 3.09 ± 0.46 n = 5 9.78 n = 1
Co 32.24 ± 17.38 n = 8 0.25 ± 0.05 n = 2 n.d. - n.d. n.d. -
Blood Cells
P+ 73.75 ± 29.25 n = 11 0.20 ± 0.07 n = 9 0.56 ± 0.19 n = 11 1.85 ± 0.38 n = 9 n.d. -
Co 63.31 ± 31.28 n = 7 0.18 ± 0.05 n = 2 0.39 ± 0.16 n = 8 1.69 ± 0.10 n = 3 n.d. -
Synovial Fluid P+ 3.00 ± 0.58 n = 2 0.92 ± 0.93 n = 3 0.21 ± 0.03 n = 2 4.31 ± 2.10 n = 6 10.63 ± 3.86 n = 4
Co 2.65 n = 1 0.17 ± 0.03 n = 2 n.d. - 3.16 ± 0.22 n = 3 10.99 ± 5.79 n = 4
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The degree of analyte conjugation with sulfate and glucuronic acid in serum was determined for
all samples (V1 and V3) and ranged from 54.29% ± 26.77% for catechin (n = 51) to 98.34% ± 4.40% for
M1 (n = 30; Table 3).
Table 3. Mean and standard deviation (SD) of the conjugation degree in serum samples (both P+ and




Current Study Former Investigation
Mean ± SD Sample Size Mean ± SD Sample Size
Catechin 54.29 26.77 n = 51 56.50 27.90 n = 5
M1 98.34 4.40 n = 30 100 *
Taxifolin 96.75 7.23 n = 11 100 *
Ferulic Acid 90.32 16.58 n = 24 100 *
Caffeic Acid 80.95 17.95 n = 10 69.40 11.80 n = 3
* A conjugation degree of 100% was assumed because no free concentrations were detectable.
3.4. Pycnogenol® Constituents and Metabolites in Blood Cell Samples
As seen with the serum samples before, basal total concentrations of the analytes with the exception
of caffeic acid were detectable at V1, with no differences between the participants assigned to the P+
or Co group. Mean concentrations of 61.38 ± 40.25 ng/mL catechin (mean ± SD), 1.68 ± 0.55 ng/mL
ferulic acid, 0.40 ± 0.18 ng/mL taxifolin, and 0.19 ± 0.08 ng/mL M1 were determined.
The analysis of blood cell samples obtained after three weeks (V3) of intake of Pycnogenol®
revealed the highest concentrations for catechin, followed by ferulic acid, M1, and taxifolin (Table 2,
panel A). No caffeic acid was detectable in any of the samples. There were no clear differences in the
concentrations determined in the P+ or Co group. When patients who admitted non-adherence to the
dietary restrictions were excluded from the analysis there was a slight trend towards higher catechin,
taxifolin, and ferulic acid levels in the P+ group compared to the control group (Table 2, panel B).
In the V3 samples of the P+ group, the open-chained ester form of M1 (M1-COOH; n = 5;
Figure S1A) was identified as well as the glutathione conjugate of M1 (M1-GSH; n = 1; Figure S1B).
In the V3 samples of the Co group, only the M1-COOH was detected in one patient sample.
3.5. Pycnogenol® Constituents and Metabolites in Synovial Fluid Samples
In the present study, synovial fluid samples were obtained at the time of knee surgery. The analysis
revealed the highest concentrations for caffeic acid, followed by ferulic acid, catechin, M1, and taxifolin
(Table 2, panel A). With the exception of taxifolin, there were no vast differences in the concentrations
of the other polyphenols.
3.6. Distribution of Pycnogenol® Constituents and Metabolites between Specimen
To exclude the chance that individual trends in distribution of the analytes were overlooked if
only group mean concentrations were considered, the individual ratios of the analyte concentrations
in the different specimen of single patients were calculated and summarized (Figure 3).




















Figure 3. Sum arized individual ratios of the centrations in different specimens of single
study participants. Columns of the interv ; dark gray) and control (Co; light grey) group
rep sent the mean and standard deviation of the i lc lated ratios. (A) Ratio cells/serum.
(B) Ratio serum/synovial fluid. (C) ati c lls synovial fluid.
The mean and standard deviations of the individual concentration ratios of the analytes in blood
cells and serum (total concentrations, V3) showed that ferulic acid (0.56 ± 0.06; n = 4), M1 (0.64 ± 0.54;
n = 5), and taxifolin (4.11 ± 3.21; n = 5) were detected in both matrices exclusively in the P+ group
(Figure 3, panel A). With ratios above 1.0, taxifolin and catechin were clearly more present in blood cells
compared to serum. In the patient group receiving 200 mg/day Pycnogenol®, the catechin distribution
into blood cells (1.65 ± 0.69; n = 11) was less pronounced than in the control group (3.14 ± 2.65; n = 7).
The individual concentration ratios of analytes in serum and synovial fluid revealed that in
both patient groups catechin was primarily distributed into serum compared to the synovial fluid
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(P+: 11.51 ± 6.04; n = 4 and Co: 15.27; n = 1; Figure 3, panel B). Caffeic acid (1.60; n = 1), taxifolin
(1.33 ± 0.38; n = 2), and ferulic acid (0.89 ± 0.32; n = 4) were present in both matrices only after intake
of Pycnogenol® and not in the control group. Ferulic acid preferentially resided in the synovial fluid,
while taxifolin and caffeic acid showed the opposite tendency. The metabolite M1 was detected both
in the P+ (1.01 ± 0.37; n = 3) and Co group (1.14; n = 1) and it appeared to be almost in equilibrium
between serum and synovial fluid.
The individual analyte distribution between blood cells and synovial fluid revealed a strong
tendency of catechin for localization within blood cells compared to the synovial fluid (Figure 3,
panel C). This was observed in both groups of the study participants (P+: 21.11 ± 13.70; n = 2 and
Co: 20.15; n = 1). Taxifolin (2.48 ± 0.90; n = 2), M1 (0.27 ± 0.27; n = 2), and ferulic acid (0.45 ± 0.15;
n = 5)) were present in both matrices exclusively in the P+ group. With a distribution ratio higher
than 1.0, taxifolin was more present in blood cells compared to synovial fluid, while M1 and ferulic
acid preferentially resided in the synovial fluid.
4. Discussion
In the present study, the in vivo distribution of constituents and metabolites of the maritime pine
extract Pycnogenol® between human serum, blood cells, and synovial fluid was investigated for the
first time. A newly developed and validated highly sensitive LC-ESI/MS/MS method allowed for
the detection and quantification of various polyphenolic compounds in synovial fluid and thereby
facilitated the proof that polyphenols are actually distributed into joints.
Analysis of samples obtained before the start of the intervention (V1) revealed that catechin and
other polyphenols were ubiquitously present in human serum samples at measurable basal levels.
Similar observations have been reported by others [21]. Based on the fact that the most controlled
condition (lifestyle/diet, timely intake of Pycnogenol® capsules) the patients were subjected to was
after their hospitalization (V3) when they were under observation of a study nurse, data analysis
focused on V3 samples comparing the intervention (P+) with the control group (Co).
As already observed in an earlier pharmacokinetic study [5], not all polyphenols were discovered
in biofluid samples of all participants, which reflected the high interindividual variability of absorption,
distribution, metabolism, and/or elimination of plant constituents. The fact that the time between
the last intake of Pycnogenol® and the collection of the specimen slightly varied around 12 h might
have also contributed to the variability of measured compound concentrations. Although the mean
polyphenol concentrations in serum, blood cells, and synovial fluid were similar in the P+ and Co
group, due to non-adherence to the dietary restrictions, distinctive observations were made in the
P+ group.
In serum samples, taxifolin and ferulic acid were only detectable in the P+, not in the Co group.
In a previous pharmacokinetic study with healthy volunteers, taxifolin was not detectable under steady
state conditions, which was most probably due to the less sensitive analytical method [5]. This is
consistent with the very low concentrations of taxifolin found in the present study. Ferulic acid has
been suggested to be a marker of consumption of maritime pine bark extract. In healthy volunteers
adhering to a low polyphenol diet, both free and conjugated ferulic acid were determined in urine
samples [22].
The conjugation degree of the investigated polyphenols in serum was high and ranged from
54.29% ± 26.77% for catechin to 98.34% ± 4.40% for M1. This is consistent with the data determined in
a former investigation [5]. However, as observed before and reported by others [22], the interindividual
variability of the conjugation degree of the analytes was high. Even in the individual person the degree
of conjugation cannot be regarded as a constant since it apparently also depends on the current analyte
concentration in the specimen [23].
Blood cells and erythrocytes represent a significant pharmacological compartment for distribution
of xenobiotics [24,25]. Individual polyphenols have been shown to accumulate in human blood cells,
macrophage-derived foam, or endothelial cells [15,16,25,26]. Notably, only low concentrations of
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M1 were found in the cellular fraction of the blood samples. This apparently contradicts previous
results showing an enhanced cellular uptake of M1, possibly via the GLUT-1 transporter, into human
erythrocytes [16]. However, M1 is subsequently subjected to an extensive intracellular metabolism [17]
which would explain the low remaining intracellular levels of M1 under steady state conditions.
Consequently, the blood cells samples of the present study were also screened for the presence of any
of the previously detected cellular M1 metabolites [17]. Indeed, in the P+ group, the open-chained
ester form of M1 (M1-COOH) and the glutathione conjugate of M1 (M1-GSH) were identified, though
not quantified. In the Co group, only M1-COOH was detected.
Sampling of synovial fluid is typically practiced for diagnostic reasons (e.g., for detection of
a septic arthritis). In research, there is great interest in osteoarthritis biomarkers such as cytokines
that might assist diagnosis or prognosis [27]. In contrast, drug concentrations are rarely reported for
synovial fluid samples. To the best of our knowledge, this is the first study investigating polyphenol
concentrations in human synovial fluid samples of patients with osteoarthritis. Similar to the results of
serum analysis, mean polyphenol concentrations were similar in the P+ and Co groups, but taxifolin
was only detectable in the P+ group. Thus, it might be a marker of Pycnogenol® consumption.
Comparing mean concentrations of the constituents and metabolites in serum, blood cells,
and synovial fluid revealed that the individual compounds did not distribute equally between
the specimen. Notably, the highest concentrations of the polyphenols were not detected in serum.
Catechin and taxifolin primarily resided within the blood cells, while M1, ferulic, and caffeic acid were
mainly present in synovial fluid samples. Generally, data on distribution of polyphenols in humans
is scarce. Although numerous investigations focus on absorption, metabolism, and elimination
of polyphenols [1,28], only a few studies investigate the distribution, for example, into human
tissues [29,30]. Distribution into or accumulation in certain body compartments might help with
understanding the effects of polyphenols despite the typically low plasma/serum concentrations that
are usually observed [1,29].
Although there were some trends towards higher analyte concentrations in the specimen of the
patients who received Pycnogenol® in the present study, the mean concentrations were similar for
both groups and were subject to high interindividual variability. It was possible that individual trends
in distribution of the analytes could have been overlooked if only group mean concentrations were
considered. Therefore, the individual ratios of the analyte concentrations in the different specimens
of single patients were calculated and summarized. Since ratios higher than 1 indicate that the
analyte is primarily distributed into, for example, blood cells compared to serum, it can be concluded
that higher concentrations of taxifolin and catechin were present in blood cells while ferulic acid
and M1 preferentially resided in serum. This observation confirms the differential distribution of
polyphenolic compounds between serum, blood cells, and synovial fluid that was already seen when
mean concentrations were examined. On an individual level, a simultaneous presence of ferulic acid,
M1, and taxifolin in blood cells and serum or cells and synovial fluid was only observed after intake of
the pine bark extract. Also, ferulic acid, taxifolin, and caffeic acid were only detected in both serum
and synovial fluid in the P+ group.
The fact that the control group received no placebo capsules to conceal the allocation to the
intervention group could be seen as a potential study limitation. However, the primary interest
was the bioanalysis of polyphenols in different specimens, and it is highly unlikely that any of the
analyte concentrations were deliberately influenced by the patients’ knowledge of group allocation.
All analytical procedures were fully validated and left no room for subjective data interpretation.
A study limitation was the small group size. Since not all polyphenols were present in the biofluid
samples of all patients due to interindividual pharmacokinetic differences and also as a result of the
non-adherence of the participants to the dietary restrictions, a statistical differentiation between the
groups was not feasible. However, the results of the present study provide a basis for sample size
calculations in future studies. Those studies would then be sufficiently powered for statistical analysis
and could reliably uncover significant differences between treatment and control groups. The fact
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that the study participants of the present study did not follow the dietary suggestions improves the
generalizability of the results since they mirror real life conditions under which foods or beverages
rich in polyphenols are occasionally or regularly consumed.
5. Conclusion
The results of this study provide the first evidence that polyphenols distribute into the synovial
fluid of patients with osteoarthritis, which supports rationalizing the results of clinical efficacy studies.
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